Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033586 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
A Phase 3 study of Polycythemia Vera, sponsored by Protagonist Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06033586: Active Phase 3 study of Polycythemia Vera, sponsored by Protagonist Therapeutics.
NCT06033586 is a Phase 3 study of Polycythemia Vera that is active but no longer recruiting, run by Protagonist Therapeutics. The registered enrollment target is 46 participants, below the 338-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06033586, a Phase 3 study of Polycythemia Vera, is active but no longer recruiting, sponsored by Protagonist Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligible to participate in this open-label study and continue treatment with rusfertide.
Primary Outcome
Median hematocrit
Conditions Studied
Interventions
- DRUG Open-label rusfertide
Study Locations (1)
Louisiana
- Pontchartrain Cancer Care - Covington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 3 |
What the registry record for NCT06033586 still lists
NCT06033586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 338-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Polycythemia Vera appearing as the primary indexed condition, and to 1 intervention - of which Open-label rusfertide is the first listed.
NCT06033586 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT06033586 about?
NCT06033586 is a clinical study titled "Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera". The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligi...
What is the current status of trial NCT06033586?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 46 participants. The study started on 2024-01-22. Estimated completion is 2027-04-01.
What conditions does trial NCT06033586 study?
This clinical trial studies the following conditions: Polycythemia Vera.
What interventions are being tested in trial NCT06033586?
The interventions under investigation include: Open-label rusfertide (DRUG).
Who is sponsoring clinical trial NCT06033586?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06033586 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06033586's enrollment target sits among peer trials
46 13th of 22 higher than 10 of 22 other Polycythemia Vera trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polycythemia Vera trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RECRUITING · Phase 3
-
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
RECRUITING · Phase 3
-
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
ACTIVE NOT RECRUITING · Phase 3
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Ruxolitinib in Thrombocythemia and Polycythemia Vera
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI